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FABRY DISEASE
 More than a hundred years ago, in 1898, two 
dermatologists, William Anderson in England and 
Johannes Fabry in Germany, independently re-
ported on patients with multiple angiokeratomas as 
well as some other symptoms. Today, the disease 
is called Anderson-Fabry or only Fabry disease, 
or angiokeratoma corporis diffusum, the latter be-
ing more often found in dermatologic literature. 
Fabry disease is a rare X-linked disorder caused 
by deficient activity of the lysosomal enzyme α-
galactosidase A, characterized by angiokerato-
mas in the skin, along with severe multiorgan 
dysfunction and premature death. The estimated 
incidence of this panethnic disease is 1:40,000 in 
male or 1:117,000 in the general population. The 
defective gene is located on chromosome Xq21-
22 and encodes for α-galactosidae. The lack of 
this enzyme activity results in progressive accu-
mulation of neutral glycosphingolipids, primarily 
globotriaosylceramide (Gb3), within lysosomes of 
cells in various organ systems, leading to a wide 
variety of progressive clinical manifestations in af-
fected individuals. The accumulation of Gb3 leads 
to various symptoms, which appear in different 
periods of life. The earliest symptoms are usually 
pain and angiokeratomas that appear in childhood 
or adolescence, the progression of disease being 
associated with cardiac, cerebral and vascular in-
volvement. The symptoms that can raise suspicion 
of Fabry disease are early stroke, left ventricular 
hypertrophy, hypohidrosis, renal insufficiency, ac-
roparesthesias and angiokeratomas.
 Angiokeratomas are a classic finding in Fabry 
disease; these are small, dark red papules, usu-
ally less than 5 mm in size, which blanch poorly 
on diascopy. They usually appear in adolescence 
and are localized in the umbilical, genital and glu-
teal region, on buttocks, and may also be located 
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periorally. The lesions are called angiokeratomas, 
however, it is specific for angiokeratomas in Fab-
ry disease that they lack keratosis, which differs 
them from other angiokeratomas.
 Making the diagnosis usually takes some time, 
and patients visit nine different specialists on an 
average before the diagnosis is established. The 
diagnosis and treatment of Fabry disease require 
team work of a general practitioner, dermatologist, 
cardiologist, genetician, ophthalmologist, gastro-
enterologist, pediatrician, neurologist and nephrol-
ogist. The diagnosis can be confirmed with labora-
tory tests confirming α-galactosidase deficiency in 
plasma, leukocytes or tears. 
 Unfortunately, in most cases the diagnosis of 
Fabry disease is made in late stages of the dis-
ease. What is the advantage of early diagnosis 
of the disease? Discovering one patient usually 
leads to other family members possibly suffering 
from Fabry disease. Early diagnosis allows for 
early introduction of appropriate therapy in order 
to stop the accumulation of GL3 before they cause 
organ damage. Until recently, Fabry disease was 
treated with supportive measures only, but today 
enzyme replacement therapy is available. Infu-
sions of agalsidase alfa or agalsidase beta result 
in clearance of Gb3.
 To date, only one case of Fabry disease has 
been diagnosed in Croatia, however, the estimat-
ed number of these patients is higher. Although 
the symptoms from other organs pose a higher 
risk for the patients life, angiokeratomas on the 
skin are a very good marker of the disease. This 
fact could lead dermatologist in search for these 
patients because early diagnosis implies a much 
better prognosis quoad vitam.
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